Citations (116)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Huixue Wang, Jie Yang, Hui Pan, Mei Chee Tai, Mohamed H Maher, Renbing Jia, Shengfang Ge & Linna Lu. (2020) Dinutuximab Synergistically Enhances the Cytotoxicity of Natural Killer Cells to Retinoblastoma Through the Perforin-Granzyme B Pathway. OncoTargets and Therapy 13, pages 3903-3920.
Read now
Read now
Abhinav Kumar, John P J Rocke & B Nirmal Kumar. (2020) Evolving treatments in high-risk neuroblastoma. Expert Opinion on Orphan Drugs 8:12, pages 497-506.
Read now
Read now
Shakeel Modak, Jean-Benoit Le Luduec, Irene Y. Cheung, Debra A. Goldman, Irina Ostrovnaya, Ekaterina Doubrovina, Ellen Basu, Brian H. Kushner, Kim Kramer, Stephen S. Roberts, Richard J. O'Reilly, Nai-Kong V. Cheung & Katharine C. Hsu. (2018) Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I study. OncoImmunology 7:8.
Read now
Read now
Sameer Sait & Shakeel Modak. (2017) Anti-GD2 immunotherapy for neuroblastoma. Expert Review of Anticancer Therapy 17:10, pages 889-904.
Read now
Read now
Claudia Maria Hattinger, Marilù Fanelli, Elisa Tavanti, Serena Vella, Stefano Ferrari, Piero Picci & Massimo Serra. (2015) Advances in emerging drugs for osteosarcoma. Expert Opinion on Emerging Drugs 20:3, pages 495-514.
Read now
Read now
Articles from other publishers (111)
Yifan Liu, Wenxu Cheng, HongYi Xin, Ran Liu, Qinqi Wang, Wenqi Cai, Xiaochun Peng, Fuyuan Yang & HongWu Xin. (2023) Nanoparticles advanced from preclinical studies to clinical trials for lung cancer therapy. Cancer Nanotechnology 14:1.
Crossref
Crossref
Winston Hibler, Glenn Merlino & Yanlin Yu. (2023) CAR NK Cell Therapy for the Treatment of Metastatic Melanoma: Potential & Prospects. Cells 12:23, pages 2750.
Crossref
Crossref
Hesam Shahabifard, Mahdi Zarei, Keihan Kookli, Nazgol Esmalian Afyouni, Narges Soltani, Sairan Maghsoodi, Ali Adili, Javad Mahmoudi, Navid Shomali & Siamak Sandoghchian Shotorbani. (2023)
An updated overview of the application of
CAR‐T
cell therapy in neurological diseases
. Biotechnology Progress 39:5.
Crossref
Crossref
Enyang He, Bowen Shi, Ziyu Liu, Kaili Chang, Hailan Zhao, Wei Zhao & Hualei Cui. (2023) Identification of the molecular subtypes and construction of risk models in neuroblastoma. Scientific Reports 13:1.
Crossref
Crossref
Xuefeng Jin & Guang-Yu Yang. (2023) Pathophysiological roles and applications of glycosphingolipids in the diagnosis and treatment of cancer diseases. Progress in Lipid Research 91, pages 101241.
Crossref
Crossref
Holger N. Lode, Ruth Ladenstein, Sascha Troschke-Meurer, Linda Struppe, Nikolai Siebert, Maxi Zumpe, Karoline Ehlert, Stefanie Huber, Evgenia Glogova, Patrick Hundsdoerfer, Angelika Eggert, Anna Zaniewska-Tekieli, Walentyna Balwierz & Aleksandra Wieczorek. (2023) Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy. Cancers 15:13, pages 3364.
Crossref
Crossref
Guangji Zhang, Yu Zhao, Zhongfeng Liu, Weihua Liu, Huantong Wu, Xuan Wang & Zhiguo Chen. (2023) GD2 CAR-T cells in combination with Nivolumab exhibit enhanced antitumor efficacy. Translational Oncology 32, pages 101663.
Crossref
Crossref
Pengcheng Zuo, Yaopeng Li, Chi He, Tantan Wang, Xu Zheng, Hao Liu, Zhen Wu, Junting Zhang, Xuebin Liao & Liwei Zhang. (2023) Anti-tumor efficacy of anti-GD2 CAR NK-92 cells in diffuse intrinsic pontine gliomas. Frontiers in Immunology 14.
Crossref
Crossref
Jaume Mora, Alicia Castañeda, Maite Gorostegui, Amalia Varo, Sara Perez-Jaume, Margarida Simao, Juan Muñoz, Moira Garraus, Cristina Larrosa, Noelia Salvador, Cinzia Lavarino, Lucas Krauel & Salvador Mañe. (2023) Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use—Updated Outcome Report. Cancers 15:9, pages 2535.
Crossref
Crossref
Hind Rafei, Rafet Basar, Katayoun Rezvani & May Daher. 2023. NK Cells in Cancer Immunotherapy: Successes and Challenges. NK Cells in Cancer Immunotherapy: Successes and Challenges
97
131
.
Nai-Kong V. Cheung, Kim Kramer, Shakeel Modak, Brian H. Kushner, Mahiuddin Ahmed, Brian Santich, Sarah Cheal & Steven Larson. 2023. Radiopharmaceutical Therapy. Radiopharmaceutical Therapy
225
252
.
Marzieh Pirzadeh & Nima Rezaei. 2022. Handbook of Cancer and Immunology. Handbook of Cancer and Immunology
1
61
.
Leah Klingel, Nikolai Siebert, Sascha Troschke-Meurer, Maxi Zumpe, Karoline Ehlert, Stefanie Huber, Hans Loibner, Oliver Mutschlechner & Holger N. Lode. (2022) Immune Response and Outcome of High-Risk Neuroblastoma Patients Immunized with Anti-Idiotypic Antibody Ganglidiomab: Results from Compassionate-Use Treatments. Cancers 14:23, pages 5802.
Crossref
Crossref
Francesco Boccalatte, Roberto Mina, Andrea Aroldi, Sarah Leone, Carter M. Suryadevara, Dimitris G. Placantonakis & Benedetto Bruno. (2022) Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors. Cancers 14:20, pages 5108.
Crossref
Crossref
Qing Wu, Wei Qian, Xiaoli Sun & Shaojie Jiang. (2022) Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. Journal of Hematology & Oncology 15:1.
Crossref
Crossref
Sofia Ahrens, Birgit Appl, Magdalena Trochimiuk, Charlotte Dücker, Gemma Feixas Serra, Albert Oliver Grau, Konrad Reinshagen & Laia Pagerols Raluy. (2022) Kigelia africana inhibits proliferation and induces cell death in stage 4 Neuroblastoma cell lines. Biomedicine & Pharmacotherapy 154, pages 113584.
Crossref
Crossref
Yiqun Zhang, Shijie Lan & Di Wu. (2022) Advanced Acral Melanoma Therapies: Current Status and Future Directions. Current Treatment Options in Oncology 23:10, pages 1405-1427.
Crossref
Crossref
Ling Wang, Shixu Li, Jun Mei & Lin Ye. (2022) Immunotherapies of retinoblastoma: Effective methods for preserving vision in the future. Frontiers in Oncology 12.
Crossref
Crossref
Zhengqing Song, Lili Lu, Zixu Gao, Qiwen Zhou, Zhiming Wang, Lei Sun & Yuhong Zhou. (2022) Immunotherapy for liposarcoma: emerging opportunities and challenges. Future Oncology 18:30, pages 3449-3461.
Crossref
Crossref
Tessa Gargett, Lisa M Ebert, Nga T H Truong, Paris M Kollis, Kristyna Sedivakova, Wenbo Yu, Erica C F Yeo, Nicole L Wittwer, Briony L Gliddon, Melinda N Tea, Rebecca Ormsby, Santosh Poonnoose, Jake Nowicki, Orazio Vittorio, David S Ziegler, Stuart M Pitson & Michael P Brown. (2022) GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma. Journal for ImmunoTherapy of Cancer 10:9, pages e005187.
Crossref
Crossref
John Anderson, Robbie G. Majzner & Paul M. Sondel. (2022) Immunotherapy of Neuroblastoma: Facts and Hopes. Clinical Cancer Research 28:15, pages 3196-3206.
Crossref
Crossref
N. S. Ivanov, D. Y. Kachanov, S. S. Larin, M. D. Mollaev, D. M. Konovalov & T. V. Shamanskaya. (2022) The role of GD2 as a diagnostic and prognostic tumor marker in neuroblastoma (literature review). Russian Journal of Pediatric Hematology and Oncology 8:4, pages 47-59.
Crossref
Crossref
Yongliang Sha, Lei Han, Bei Sun & Qiang Zhao. (2022) Identification of a Glycosyltransferase Signature for Predicting Prognosis and Immune Microenvironment in Neuroblastoma. Frontiers in Cell and Developmental Biology 9.
Crossref
Crossref
Yuren Xia, Xin Li, Xiangdong Tian & Qiang Zhao. (2021) Identification of a Five-Gene Signature Derived From MYCN Amplification and Establishment of a Nomogram for Predicting the Prognosis of Neuroblastoma. Frontiers in Molecular Biosciences 8.
Crossref
Crossref
John T. Keane & Avery D. PoseyJr.Jr.. (2021) Chimeric Antigen Receptors Expand the Repertoire of Antigenic Macromolecules for Cellular Immunity. Cells 10:12, pages 3356.
Crossref
Crossref
Jaume Mora, Alicia Castañeda, Maite Gorostegui, Vicente Santa‐María, Moira Garraus, Juan Pablo Muñoz, Amalia Varo, Sara Perez‐Jaume & Salvador Mañe. (2021) Naxitamab combined with granulocyte‐macrophage colony‐stimulating factor as consolidation for high‐risk neuroblastoma patients in complete remission. Pediatric Blood & Cancer 68:10.
Crossref
Crossref
Zili Lin, Ziyi Wu & Wei Luo. (2021) Chimeric Antigen Receptor T-Cell Therapy: The Light of Day for Osteosarcoma. Cancers 13:17, pages 4469.
Crossref
Crossref
Francesca Palmisani, Heinrich Kovar, Leo Kager, Gabriele Amann, Martin Metzelder & Michael Bergmann. (2021) Systematic review of the immunological landscape of Wilms tumors. Molecular Therapy - Oncolytics 22, pages 454-467.
Crossref
Crossref
Godfred O. Sabbih & Michael K. Danquah. (2021) Neuroblastoma GD2 Expression and Computational Analysis of Aptamer-Based Bioaffinity Targeting. International Journal of Molecular Sciences 22:16, pages 9101.
Crossref
Crossref
Ruey-Herng Lee, Yu-Jen Wang, Ting-Yen Lai, Tsui-Ling Hsu, Po-Kai Chuang, Han-Chung Wu & Chi-Huey Wong. (2021) Combined Effect of Anti-SSEA4 and Anti-Globo H Antibodies on Breast Cancer Cells. ACS Chemical Biology 16:8, pages 1526-1537.
Crossref
Crossref
Henrietta O. Fasanya, Pablo J. Dopico, Zachary Yeager, Z. Hugh Fan & Dietmar W. Siemann. (2021) Using a combination of gangliosides and cell surface vimentin as surface biomarkers for isolating osteosarcoma cells in microfluidic devices. Journal of Bone Oncology 28, pages 100357.
Crossref
Crossref
Sophia B. Strobel, Devayani Machiraju, Ingrid Hülsmeyer, Jürgen C. Becker, Annette Paschen, Dirk Jäger, Winfried S. Wels, Michael Bachmann & Jessica C. Hassel. (2021) Expression of Potential Targets for Cell-Based Therapies on Melanoma Cells. Life 11:4, pages 269.
Crossref
Crossref
Nora Bloise, Mohammad Okkeh, Elisa Restivo, Cristina Della Pina & Livia Visai. (2021) Targeting the “Sweet Side” of Tumor with Glycan-Binding Molecules Conjugated-Nanoparticles: Implications in Cancer Therapy and Diagnosis. Nanomaterials 11:2, pages 289.
Crossref
Crossref
Brian H. Santich, Sarah M. Cheal, Mahiuddin Ahmed, Michael R. McDevitt, Ouathek Ouerfelli, Guangbin Yang, Darren R. Veach, Edward K. Fung, Mitesh Patel, Daniela Burnes Vargas, Aiza A. Malik, Hong-Fen Guo, Pat B. Zanzonico, Sebastien Monette, Adam O. Michel, Charles M. Rudin, Steven M. Larson & Nai K. Cheung. (2021) A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted Radioimmunotherapy. Clinical Cancer Research 27:2, pages 532-541.
Crossref
Crossref
Fabio Morandi, Federica Sabatini, Marina Podestà & Irma Airoldi. (2021) Immunotherapeutic Strategies for Neuroblastoma: Present, Past and Future. Vaccines 9:1, pages 43.
Crossref
Crossref
Divya Thomas, Ashok Kumar Rathinavel & Prakash Radhakrishnan. (2021) Altered glycosylation in cancer: A promising target for biomarkers and therapeutics. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1875:1, pages 188464.
Crossref
Crossref
Piamsiri Sawaisorn, Korakot Atjanasuppat, Usanarat Anurathapan, Somchai Chutipongtanate & Suradej Hongeng. (2020) Strategies to Improve Chimeric Antigen Receptor Therapies for Neuroblastoma. Vaccines 8:4, pages 753.
Crossref
Crossref
Karin Straathof, Barry Flutter, Rebecca WallaceNeha Jain, Thalia Loka, Sarita DepaniGary WrightSimon Thomas, Gordon Weng-Kit Cheung, Talia Gileadi, Sian Stafford, Evangelia Kokalaki, Jack Barton, Clare MarriottDyanne Rampling, Olumide Ogunbiyi, Ayse U. AkarcaTeresa Marafioti, Sarah InglottKimberly Gilmour, Muhammad Al-Hajj, William DayKieran McHugh, Lorenzo Biassoni, Natalie Sizer, Claire BartonDavid EdwardsIlaria DragoniJulie SilvesterKaren Dyer, Stephanie Traub, Lily ElsonSue BrookNigel Westwood, Lesley Robson, Ami BediKaren Howe, Ailish BarryCatriona Duncan, Giuseppe Barone, Martin Pule & John Anderson. (2020) Antitumor activity without on-target off-tumor toxicity of GD2–chimeric antigen receptor T cells in patients with neuroblastoma. Science Translational Medicine 12:571.
Crossref
Crossref
Gils Jose, Yu-Jen Lu, Jung-Tung Hung, Alice L. Yu & Jyh-Ping Chen. (2020) Co-Delivery of CPT-11 and Panobinostat with Anti-GD2 Antibody Conjugated Immunoliposomes for Targeted Combination Chemotherapy. Cancers 12:11, pages 3211.
Crossref
Crossref
Elsa Irving, Aristides D. Tagalakis, Ruhina Maeshima, Stephen L. Hart, Simon Eaton, Ari Lehtonen & Andrew W. Stoker. (2020) The liposomal delivery of hydrophobic oxidovanadium complexes imparts highly effective cytotoxicity and differentiating capacity in neuroblastoma tumour cells. Scientific Reports 10:1.
Crossref
Crossref
Ralph N. D. Luetscher, Tanya R. McKitrick, Chao Gao, Akul Y. Mehta, Alyssa M. McQuillan, Robert Kardish, Kayluz Frias Boligan, Xuezheng Song, Lenette Lu, Jamie Heimburg-Molinaro, Stephan von Gunten, Galit Alter & Richard D. Cummings. (2020) Unique repertoire of anti-carbohydrate antibodies in individual human serum. Scientific Reports 10:1.
Crossref
Crossref
S. Elizabeth Franks, Benjamin Wolfson & James W. Hodge. (2020) Natural Born Killers: NK Cells in Cancer Therapy. Cancers 12:8, pages 2131.
Crossref
Crossref
Mitchell B. Diccianni, Katarzyna Kempińska, Jon A. Gangoti, Alice L. Yu & Linda S. Sorkin. (2020) Anti-GD2 induced allodynia in rats can be reduced by pretreatment with DFMO. PLOS ONE 15:7, pages e0236115.
Crossref
Crossref
Bassel Nazha, Cengiz Inal & Taofeek K. Owonikoko. (2020) Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy. Frontiers in Oncology 10.
Crossref
Crossref
Jeong A. Park & Nai-Kong V. Cheung. (2020) Targets and Antibody Formats for Immunotherapy of Neuroblastoma. Journal of Clinical Oncology 38:16, pages 1836-1848.
Crossref
Crossref
Maxim Sorokin, Irina Kholodenko, Daniel Kalinovsky, Tatyana Shamanskaya, Igor Doronin, Dmitry Konovalov, Aleksei Mironov, Denis Kuzmin, Daniil Nikitin, Sergey Deyev, Anton Buzdin & Roman Kholodenko. (2020) RNA Sequencing-Based Identification of Ganglioside GD2-Positive Cancer Phenotype. Biomedicines 8:6, pages 142.
Crossref
Crossref
Sascha Marx, Fabian Wilken, Isabel Wagner, Madlen Marx, Sascha Troschke-Meurer, Maxi Zumpe, Sandra Bien-Moeller, Martin Weidemeier, Joerg Baldauf, Steffen K. Fleck, Bernhard H. Rauch, Henry W. S. Schroeder, Holger Lode & Nikolai Siebert. (2020) GD2 targeting by dinutuximab beta is a promising immunotherapeutic approach against malignant glioma. Journal of Neuro-Oncology 147:3, pages 577-585.
Crossref
Crossref
Kristopher R. Bosse, Robbie G. Majzner, Crystal L. Mackall & John M. Maris. (2020) Immune-Based Approaches for the Treatment of Pediatric Malignancies. Annual Review of Cancer Biology 4:1, pages 353-370.
Crossref
Crossref
Clodagh P. O’Neill & Róisín M. Dwyer. (2020) Nanoparticle-Based Delivery of Tumor Suppressor microRNA for Cancer Therapy. Cells 9:2, pages 521.
Crossref
Crossref
Nicola Mitwasi, Anja Feldmann, Claudia Arndt, Stefanie Koristka, Nicole Berndt, Justyna Jureczek, Liliana R. Loureiro, Ralf Bergmann, Domokos Máthé, Nikolett Hegedüs, Tibor Kovács, Congcong Zhang, Pranav Oberoi, Elke Jäger, Barbara Seliger, Claudia Rössig, Achim Temme, Jiri Eitler, Torsten Tonn, Marc Schmitz, Jessica C. Hassel, Dirk Jäger, Winfried S. Wels & Michael Bachmann. (2020) “UniCAR”-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells. Scientific Reports 10:1.
Crossref
Crossref
Akanksha Limaye, Jajoriya Sweta, Maddala Madhavi, Urvy Mudgal, Sourav Mukherjee, Shreshtha Sharma, Tajamul Hussain, Anuraj Nayarisseri & Sanjeev Kumar Singh. (2020) In Silico Insights on GD2 : A Potential Target for Pediatric Neuroblastoma. Current Topics in Medicinal Chemistry 19:30, pages 2766-2781.
Crossref
Crossref
Cheng ji, Fengtao You, Tingting Zhang, Shuangshuang Fan, Zhichao Han, Shufen Xiang, Yinyan Wang, Binjie Sheng, Tian Wang, Gangli An, Huimin Meng & Lin Yang. (2020) Novel anti-GD2 CAR-T cells exhibit superior cytotoxicity against neuroblastoma. European Journal of Inflammation 18, pages 205873922096119.
Crossref
Crossref
Sophie Groux-Degroote, Sumeyye Cavdarli, Kenji Uchimura, Fabrice Allain & Philippe Delannoy. 2020. Inflammatory Disorders, Part A. Inflammatory Disorders, Part A
111
156
.
Izhar S. Batth & Shulin Li. 2020. Current Advances in Osteosarcoma. Current Advances in Osteosarcoma
169
178
.
Marianna Zolotovskaia, Maxim Sorokin, Andrew Garazha, Nikolay Borisov & Anton Buzdin. 2020. Nucleic Acid Detection and Structural Investigations. Nucleic Acid Detection and Structural Investigations
207
234
.
Lena Andersch, Josefine Radke, Anika Klaus, Silke Schwiebert, Annika Winkler, Elisa Schumann, Laura Grunewald, Felix Zirngibl, Carina Flemmig, Michael C. Jensen, Claudia Rossig, Antonia Joussen, Anton Henssen, Angelika Eggert, Johannes H. Schulte & Annette Künkele. (2019) CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing. BMC Cancer 19:1.
Crossref
Crossref
Irina V. Kholodenko, Daniel V. Kalinovsky, Elena V. Svirshchevskaya, Igor I. Doronin, Maria V. Konovalova, Alexey V. Kibardin, Tatyana V. Shamanskaya, Sergey S. Larin, Sergey M. Deyev & Roman V. Kholodenko. (2019) Multimerization through Pegylation Improves Pharmacokinetic Properties of scFv Fragments of GD2-Specific Antibodies. Molecules 24:21, pages 3835.
Crossref
Crossref
Carlos Rodríguez-Nogales, Rosa Noguera, Patrick Couvreur & María J. Blanco-Prieto. (2019) Therapeutic Opportunities in Neuroblastoma Using Nanotechnology. Journal of Pharmacology and Experimental Therapeutics 370:3, pages 625-635.
Crossref
Crossref
Marina Ollé Hurtado, Jolien Wolbert, Jonathan Fisher, Barry Flutter, Sian Stafford, Jack Barton, Neha Jain, Giuseppe Barone, Yvonne Majani & John Anderson. (2019) Tumor infiltrating lymphocytes expanded from pediatric neuroblastoma display heterogeneity of phenotype and function. PLOS ONE 14:8, pages e0216373.
Crossref
Crossref
Elizabeth R. Butch, Paul E. Mead, Victor Amador Diaz, Heather Tillman, Elizabeth Stewart, Jitendra K. Mishra, Jieun Kim, Armita Bahrami, Jason L.J. Dearling, Alan B. Packard, Shana V. Stoddard, Amy L. Vāvere, Yuanyuan Han, Barry L. Shulkin & Scott E. Snyder. (2019)
Positron Emission Tomography Detects
In Vivo
Expression of Disialoganglioside GD2 in Mouse Models of Primary and Metastatic Osteosarcoma
. Cancer Research 79:12, pages 3112-3124.
Crossref
Crossref
Parnian Jabbari, Sara Hanaei & Nima Rezaei. (2019) State of the art in immunotherapy of neuroblastoma. Immunotherapy 11:9, pages 831-850.
Crossref
Crossref
Julie Voeller & Paul M. Sondel. (2019) Advances in Anti-GD2 Immunotherapy for Treatment of High-risk Neuroblastoma. Journal of Pediatric Hematology/Oncology 41:3, pages 163-169.
Crossref
Crossref
Vasyl Eisenberg, Shiran Hoogi, Astar Shamul, Tilda Barliya & Cyrille J. Cohen. (2019) T-cells “à la CAR-T(e)” – Genetically engineering T-cell response against cancer. Advanced Drug Delivery Reviews 141, pages 23-40.
Crossref
Crossref
Marianna A. Zolotovskaia, Maxim I. Sorokin, Anna A. Emelianova, Nikolay M. Borisov, Denis V. Kuzmin, Pieter Borger, Andrew V. Garazha & Anton A. Buzdin. (2019) Pathway Based Analysis of Mutation Data Is Efficient for Scoring Target Cancer Drugs. Frontiers in Pharmacology 10.
Crossref
Crossref
欣蓉 谢. (2019) Diagnosis and Progress in Biological Treatment of Osteosarcoma. Hans Journal of Biomedicine 09:03, pages 114-120.
Crossref
Crossref
Michael P Brown, Lisa M Ebert & Tessa Gargett. (2019) Clinical chimeric antigen receptor‐T cell therapy: a new and promising treatment modality for glioblastoma. Clinical & Translational Immunology 8:5, pages e1050.
Crossref
Crossref
Jiayi Yu, Xiaowen Wu, Junya Yan, Huan Yu, Longwen Xu, Zhihong Chi, Xinan Sheng, Lu Si, Chuanliang Cui, Jie Dai, Meng Ma, Tianxiao Xu, Yan Kong & Jun Guo. (2018) Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients. Journal of Hematology & Oncology 11:1.
Crossref
Crossref
C.M. Busch, A.V. Desai, G.S. Moorthy, E. Fox & F.M. Balis. (2018) A validated HPLC-MS/MS method for estimating the concentration of the ganglioside, GD2, in human plasma or serum. Journal of Chromatography B 1102-1103, pages 60-65.
Crossref
Crossref
Roger Sandhoff & Konrad Sandhoff. (2018) Emerging concepts of ganglioside metabolism. FEBS Letters 592:23, pages 3835-3864.
Crossref
Crossref
Carlos Rodríguez-Nogales, Yolanda González-Fernández, Azucena Aldaz, Patrick Couvreur & María J. Blanco-Prieto. (2018) Nanomedicines for Pediatric Cancers. ACS Nano 12:8, pages 7482-7496.
Crossref
Crossref
Irina V. Kholodenko, Daniel V. Kalinovsky, Igor I. Doronin, Sergey M. Deyev & Roman V. Kholodenko. (2018) Neuroblastoma Origin and Therapeutic Targets for Immunotherapy. Journal of Immunology Research 2018, pages 1-25.
Crossref
Crossref
Emily E. Bosco, R. James Christie, Rosa Carrasco, Darrin Sabol, Jiping Zha, Karma DaCosta, Lee Brown, Maureen Kennedy, John Meekin, Sandrina Phipps, Joanne Ayriss, Qun Du, Binyam Bezabeh, Partha Chowdhury, Shannon Breen, Cui Chen, Molly Reed, MaryJane Hinrichs, Haihong Zhong, Zhan Xiao, Rakesh Dixit, Ronald Herbst & David A. Tice. (2018) Preclinical evaluation of a GFRA1 targeted antibody-drug conjugate in breast cancer. Oncotarget 9:33, pages 22960-22975.
Crossref
Crossref
Maria-Luisa Schubert, Jean-Marc Hoffmann, Peter Dreger, Carsten Müller-Tidow & Michael Schmitt. (2018) Chimeric antigen receptor transduced T cells: Tuning up for the next generation. International Journal of Cancer 142:9, pages 1738-1747.
Crossref
Crossref
Miriam Palacios, Ricardo Tampe, Miguel Del Campo, Ta-Ying Zhong, Mercedes N. López, Flavio Salazar-Onfray & María Inés Becker. (2018) Antitumor activity and carrier properties of novel hemocyanins coupled to a mimotope of GD2 ganglioside. European Journal of Medicinal Chemistry 150, pages 74-86.
Crossref
Crossref
Shima Gholizadeh, Emmy M. Dolman, Rebecca Wieriks, Rolf W. Sparidans, Wim E. Hennink & Robbert J. Kok. (2018) Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells. Pharmaceutical Research 35:4.
Crossref
Crossref
Kathleen Birley, Kerry Chester & John Anderson. (2018) Antibody based therapy for childhood solid cancers. Current Opinion in Chemical Engineering 19, pages 153-162.
Crossref
Crossref
Sharareh Gholamin, Hamed Mirzaei, Seyed‐Mostafa Razavi, Seyed Mahdi Hassanian, Leila Saadatpour, Aria Masoudifar, Soodabeh ShahidSales & Amir Avan. (2017) GD2‐targeted immunotherapy and potential value of circulating microRNAs in neuroblastoma. Journal of Cellular Physiology 233:2, pages 866-879.
Crossref
Crossref
Roger Sandhoff, Heike Schulze & Konrad Sandhoff. 2018. Gangliosides in Health and Disease. Gangliosides in Health and Disease
1
62
.
Sophie Groux-Degroote, Macarena Rodríguez-Walker, Justine H. Dewald, Jose L. Daniotti & Philippe Delannoy. 2018. Gangliosides in Health and Disease. Gangliosides in Health and Disease
197
227
.
Weijun Wei, Emily B. Ehlerding, Xiaoli Lan, Quanyong Luo & Weibo Cai. (2017) PET and SPECT imaging of melanoma: the state of the art. European Journal of Nuclear Medicine and Molecular Imaging 45:1, pages 132-150.
Crossref
Crossref
Aaron M. Goodman, Tiffany N. Tanaka & Dan S. Kaufman. 2018. Early Phase Cancer Immunotherapy. Early Phase Cancer Immunotherapy
133
184
.
Miho Nakajima & Shakeel Modak. 2018. Immunotherapy for Pediatric Malignancies. Immunotherapy for Pediatric Malignancies
217
242
.
Isabel Corraliza-Gorjón, Beatriz Somovilla-Crespo, Silvia Santamaria, Jose A. Garcia-Sanz & Leonor Kremer. (2017) New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness. Frontiers in Immunology 8.
Crossref
Crossref
Nicola Mitwasi, Anja Feldmann, Ralf Bergmann, Nicole Berndt, Claudia Arndt, Stefanie Koristka, Alexandra Kegler, Justyna Jureczek, Anja Hoffmann, Armin Ehninger, Marc Cartellieri, Susann Albert, Claudia Rossig, Gerhard Ehninger, Jens Pietzsch, Jörg Steinbach & Michael Bachmann. (2017) Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells. Oncotarget 8:65, pages 108584-108603.
Crossref
Crossref
Thanh-Phuong Le & To-Ha Thai. (2017) The State of Cellular Adoptive Immunotherapy for Neuroblastoma and Other Pediatric Solid Tumors. Frontiers in Immunology 8.
Crossref
Crossref
Kristopher R. Bosse, Pichai Raman, Zhongyu Zhu, Maria Lane, Daniel Martinez, Sabine Heitzeneder, Komal S. Rathi, Nathan M. Kendsersky, Michael Randall, Laura Donovan, Sorana Morrissy, Robyn T. Sussman, Doncho V. Zhelev, Yang Feng, Yanping Wang, Jennifer Hwang, Gonzalo Lopez, Jo Lynne Harenza, Jun S. Wei, Bruce Pawel, Tricia Bhatti, Mariarita Santi, Arupa Ganguly, Javed Khan, Marco A. Marra, Michael D. Taylor, Dimiter S. Dimitrov, Crystal L. Mackall & John M. Maris. (2017) Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma. Cancer Cell 32:3, pages 295-309.e12.
Crossref
Crossref
Hua Li & Yangbing Zhao. (2017) Increasing the safety and efficacy of chimeric antigen receptor T cell therapy. Protein & Cell 8:8, pages 573-589.
Crossref
Crossref
Sophie Groux-Degroote, Yann Guérardel & Philippe Delannoy. (2017) Gangliosides: Structures, Biosynthesis, Analysis, and Roles in Cancer. ChemBioChem 18:13, pages 1146-1154.
Crossref
Crossref
Carles Monterrubio, Sonia Paco, Nagore G. Olaciregui, Guillem Pascual-Pasto, Monica Vila-Ubach, Maria Cuadrado-Vilanova, M. Mar Ferrandiz, Helena Castillo-Ecija, Romina Glisoni, Nataliya Kuplennik, Achim Jungbluth, Carmen de Torres, Cinzia Lavarino, N.K.V. Cheung, Jaume Mora, Alejandro Sosnik & Angel M. Carcaboso. (2017) Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8. Journal of Controlled Release 255, pages 108-119.
Crossref
Crossref
Huan-huan Sha, Dan-dan Wang, Da-li Yan, Yong Hu, Su-jin Yang, Si-wen Liu & Ji-feng Feng. (2017) Chimaeric antigen receptor T-cell therapy for tumour immunotherapy. Bioscience Reports 37:1.
Crossref
Crossref
Michael Sun, Ngoc Ha, Duc-Hung Pham, Megan Frederick, Bandana Sharma, Chie Naruse, Masahide Asano, Matthew E. Pipkin, Rani E. George & To-Ha Thai. (2017) Cbx3/HP1γ deficiency confers enhanced tumor-killing capacity on CD8+ T cells. Scientific Reports 7:1.
Crossref
Crossref
Jürgen Kopitz. (2016) Lipid glycosylation: a primer for histochemists and cell biologists. Histochemistry and Cell Biology 147:2, pages 175-198.
Crossref
Crossref
Zhihui Liu & Carol J. Thiele. 2017. Diagnostic and Therapeutic Nuclear Medicine for Neuroendocrine Tumors. Diagnostic and Therapeutic Nuclear Medicine for Neuroendocrine Tumors
83
125
.
Alina D. Zamfir. 2017. Proteomics for Drug Discovery. Proteomics for Drug Discovery
109
128
.
Roswitha Schumacher-Kuckelkorn, Ruth Volland, Anke Gradehandt, Barbara Hero, Thorsten Simon & Frank Berthold. (2017) Lack of immunocytological GD2 expression on neuroblastoma cells in bone marrow at diagnosis, during treatment, and at recurrence*. Pediatric Blood & Cancer 64:1, pages 46-56.
Crossref
Crossref
Ludger Johannes, Christian Wunder & Massiullah Shafaq-Zadah. (2016) Glycolipids and Lectins in Endocytic Uptake Processes. Journal of Molecular Biology 428:24, pages 4792-4818.
Crossref
Crossref
Rachid C. Baz, Jeffrey A. Zonder, Cristina Gasparetto, Frederic J. Reu & Vincent Strout. (2016) Phase I Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Patients with Previously Treated Multiple Myeloma. Oncology and Therapy 4:2, pages 287-301.
Crossref
Crossref
Jon Arne Søreide, Erling Sandøy Undersrud, Mohammed S. S. Al-Saiddi, Tore Tholfsen & Kjetil Søreide. (2016) Primary Leiomyosarcoma of the Pancreas—a Case Report and a Comprehensive Review. Journal of Gastrointestinal Cancer 47:4, pages 358-365.
Crossref
Crossref
Roberto Luksch, Maria Rita Castellani, Paola Collini, Bruno De Bernardi, Massimo Conte, Claudio Gambini, Lorenza Gandola, Alberto Garaventa, Davide Biasoni, Marta Podda, Angela Rita Sementa, Gemma Gatta & Gian Paolo Tonini. (2016) Neuroblastoma (Peripheral neuroblastic tumours). Critical Reviews in Oncology/Hematology 107, pages 163-181.
Crossref
Crossref
Jan Müller, Robin Reichel, Sebastian Vogt, Stefan P. Müller, Wolfgang Sauerwein, Wolfgang Brandau, Angelika Eggert & Alexander Schramm. (2016) Identification and Tumour-Binding Properties of a Peptide with High Affinity to the Disialoganglioside GD2. PLOS ONE 11:10, pages e0163648.
Crossref
Crossref
Adrienne H. Long, Steven L. Highfill, Yongzhi Cui, Jillian P. Smith, Alec J. Walker, Sneha Ramakrishna, Rana El-Etriby, Susana Galli, Maria G. Tsokos, Rimas J. Orentas & Crystal L. Mackall. (2016) Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas. Cancer Immunology Research 4:10, pages 869-880.
Crossref
Crossref
Poh-Choo Pang, Stuart M. Haslam, Anne Dell & Gary F. Clark. (2016) The human fetoembryonic defense system hypothesis: Twenty years on. Molecular Aspects of Medicine 51, pages 71-88.
Crossref
Crossref
A. A. Zubareva, A. A. Boyko, I. V. Kholodenko, F. N. Rozov, M. V. Larina, T. K. Aliev, I. I. Doronin, P. A. Vishnyakova, I. M. Molotkovskaya & R. V. Kholodenko. (2016) Chitosan nanoparticles targeted to the tumor-associated ganglioside GD2. Russian Journal of Bioorganic Chemistry 42:5, pages 532-545.
Crossref
Crossref
Guillem Pascual-Pasto, Nagore G. Olaciregui, Monica Vila-Ubach, Sonia Paco, Carles Monterrubio, Eva Rodriguez, Ursula Winter, Mireia Batalla-Vilacis, Jaume Catala, Hector Salvador, Andreu Parareda, Paula Schaiquevich, Mariona Suñol, Jaume Mora, Cinzia Lavarino, Carmen de Torres, Guillermo L. Chantada & Angel M. Carcaboso. (2016) Preclinical platform of retinoblastoma xenografts recapitulating human disease and molecular markers of dissemination. Cancer Letters 380:1, pages 10-19.
Crossref
Crossref
Hollie J. Jackson, Sarwish Rafiq & Renier J. Brentjens. (2016) Driving CAR T-cells forward. Nature Reviews Clinical Oncology 13:6, pages 370-383.
Crossref
Crossref
Gregory T. Wurz, Chiao-Jung Kao & Michael W. DeGregorio. (2015) Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential. Therapeutic Advances in Medical Oncology 8:1, pages 4-31.
Crossref
Crossref
Peifu Jiao, Mario Otto, Qiaohong Geng, Chencan Li, Faming Li, Elizabeth R. Butch, Scott E. Snyder, Hongyu Zhou & Bing Yan. (2016) Enhancing both CT imaging and natural killer cell-mediated cancer cell killing by a GD2-targeting nanoconstruct. Journal of Materials Chemistry B 4:3, pages 513-520.
Crossref
Crossref
Natalia Lapteva, Robin Parihar, Lisa A. Rollins, Adrian P. Gee & Cliona M. Rooney. 2016. Natural Killer Cells. Natural Killer Cells
195
202
.
PAN MA, QIANG HE, WEI LI, XIANLIANG LI, HUAMIN HAN, MENGMENG JIN, CHANGZHEN LIU, HUA TAO, JUAN MA & BIN GAO. (2015) Anti-CD3 x EGFR bispecific antibody redirects cytokine-induced killer cells to glioblastoma in vitro and in vivo. Oncology Reports 34:5, pages 2567-2575.
Crossref
Crossref
Malvina Prapa, Sara Caldrer, Carlotta Spano, Marco Bestagno, Giulia Golinelli, Giulia Grisendi, Tiziana Petrachi, Pierfranco Conte, Edwin M. Horwitz, Dario Campana, Paolo Paolucci & Massimo Dominici. (2015) A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing. Oncotarget 6:28, pages 24884-24894.
Crossref
Crossref
Stephen S. Roberts, Alexander J. Chou & Nai-Kong V. Cheung. (2015) Immunotherapy of Childhood Sarcomas. Frontiers in Oncology 5.
Crossref
Crossref